BR112021013952A2 - Métodos de indução de uma resposta imunológica anticâncer - Google Patents

Métodos de indução de uma resposta imunológica anticâncer

Info

Publication number
BR112021013952A2
BR112021013952A2 BR112021013952A BR112021013952A BR112021013952A2 BR 112021013952 A2 BR112021013952 A2 BR 112021013952A2 BR 112021013952 A BR112021013952 A BR 112021013952A BR 112021013952 A BR112021013952 A BR 112021013952A BR 112021013952 A2 BR112021013952 A2 BR 112021013952A2
Authority
BR
Brazil
Prior art keywords
cancer cells
immunologically
pretreated
cells
inducing
Prior art date
Application number
BR112021013952A
Other languages
English (en)
Portuguese (pt)
Inventor
D Smith Charles
W Maines Lynn
Original Assignee
Apogee Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogee Biotechnology Corp filed Critical Apogee Biotechnology Corp
Publication of BR112021013952A2 publication Critical patent/BR112021013952A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112021013952A 2019-01-16 2020-01-16 Métodos de indução de uma resposta imunológica anticâncer BR112021013952A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962792996P 2019-01-16 2019-01-16
PCT/US2020/013817 WO2020150434A1 (en) 2019-01-16 2020-01-16 Methods of inducing an anti-cancer immune response

Publications (1)

Publication Number Publication Date
BR112021013952A2 true BR112021013952A2 (pt) 2021-11-16

Family

ID=71613420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013952A BR112021013952A2 (pt) 2019-01-16 2020-01-16 Métodos de indução de uma resposta imunológica anticâncer

Country Status (11)

Country Link
US (1) US20220062250A1 (https=)
EP (1) EP3911681A4 (https=)
JP (1) JP7693206B2 (https=)
KR (1) KR20210118101A (https=)
CN (1) CN113574068B (https=)
AU (1) AU2020208414A1 (https=)
BR (1) BR112021013952A2 (https=)
CA (1) CA3126818A1 (https=)
IL (1) IL284695A (https=)
MX (1) MX2021008591A (https=)
WO (1) WO2020150434A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160692A1 (en) * 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
CA3202416A1 (en) * 2020-12-16 2022-06-23 Pieter Fokko VAN LOO Multispecific antibodies for the treatment of cancer
CN116217468A (zh) * 2023-02-22 2023-06-06 天津民祥药业有限公司 一种奥帕尼布的新型合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
WO2008028968A2 (en) * 2006-09-08 2008-03-13 Institut Gustave Roussy Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
EP2384118A4 (en) * 2008-12-30 2012-01-11 Musc Found For Res Dev SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE
WO2017060771A2 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
CA3061201A1 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Also Published As

Publication number Publication date
JP2022517415A (ja) 2022-03-08
CN113574068A (zh) 2021-10-29
CN113574068B (zh) 2024-07-23
WO2020150434A1 (en) 2020-07-23
US20220062250A1 (en) 2022-03-03
EP3911681A1 (en) 2021-11-24
IL284695A (en) 2021-08-31
CA3126818A1 (en) 2020-07-23
AU2020208414A1 (en) 2021-07-29
KR20210118101A (ko) 2021-09-29
MX2021008591A (es) 2021-10-13
EP3911681A4 (en) 2022-11-02
JP7693206B2 (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
BR112021013952A2 (pt) Métodos de indução de uma resposta imunológica anticâncer
BR112023002724A2 (pt) Neoantígenos ras e seus usos
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
BR112018074192A8 (pt) Método para tratamento de um sujeito, método para produzir uma composição celular, composição de células, composição de vacina e kit
BR112018069251A2 (pt) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
BR112018072714A2 (pt) composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
ES2721179T3 (es) Composiciones cosméticas y farmacéuticas a base de líquido de incubación de pescado
BR112021025116A2 (pt) Células linfocíticas ativadas e métodos de uso das mesmas para tratar câncer e condições infecciosas
PH12022551078A1 (en) Combination therapy to treat brain cancer
BR112017019776A2 (pt) proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
ES336810A1 (es) Un metodo para producir una cepa de celulas.
MX2022007779A (es) Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.
Yang et al. Restoring tumor antigenicity activates the “bystander” T cell immune cycle
Bollyky et al. IL‐10 Induction from Implants Delivering Pancreatic Islets and Hyaluronan
WO2017123666A3 (en) In vivo positron emission tomography-based perfusion/blood pool imaging using labeled erythrocytes
Skerman et al. Experimental observations on prophylactic and therapeutic vaccination against foot-rot in sheep
EA202090990A1 (ru) Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител
Zeng et al. Skin-grafting and dendritic cell “boosted” humanized mouse models allow the pre-clinical evaluation of therapeutic cancer vaccines
Liegel et al. Post-transplant vaccination with a personalized dendritic Cell/AML fusion cell vaccine for prevention of relapse
Iman Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: a prospective randomized clinical trial
GUAN et al. Clinical analysis of lasting remission of high-risk acute lymphoblastic leukemia in children after severe infection
Hospers et al. Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen
He et al. The Role of N-acetylcysteine Amide in Acute Graft-versus-host Disease Mouse Model
TENG et al. Anti-tumor activities of CIK cells derived from lymph nodes of lung cancer patients
Tapias et al. A 3D model for lung cancer based on decellularized lung scaffolds allows for in vitro testing of viral oncolysis